A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

Peer Review reports

Original Submission
3 Apr 2020	Submitted	Original manuscript
28 Jun 2020	Reviewed	Reviewer Report - Michel M. van Den Heuvel
26 Jul 2020	Reviewed	Reviewer Report
31 Jul 2020	Author responded	Author comments - Kyoichi Kaira
Resubmission - Version 2
31 Jul 2020	Submitted	Manuscript version 2
5 Aug 2020	Author responded	Author comments - Kyoichi Kaira
Resubmission - Version 3
5 Aug 2020	Submitted	Manuscript version 3
25 Aug 2020	Reviewed	Reviewer Report
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
14 Sep 2020	Editorially accepted
6 Oct 2020	Article published	10.1186/s12885-020-07406-y

Back to article page